Switching from Vyndamax to Vyndaqel is a concern for many with ATTR wild-type amyloidosis. Both medications contain the same active ingredient, tafamidis, and work by stabilizing TTR proteins to prevent amyloid fibril formation. Here are some key points to consider:

- Active Ingredient: Both Vyndamax and Vyndaqel contain Show Full Answer

Switching from Vyndamax to Vyndaqel is a concern for many with ATTR wild-type amyloidosis. Both medications contain the same active ingredient, tafamidis, and work by stabilizing TTR proteins to prevent amyloid fibril formation. Here are some key points to consider:

- Active Ingredient: Both Vyndamax and Vyndaqel contain tafamidis, so their mechanism of action is the same.
- Dosage Form: Vyndamax is typically taken as a single 61 mg capsule, while Vyndaqel is taken as four 20 mg capsules daily.
- Insurance and Assistance: It's common for insurance companies to have different coverage policies. Working with your doctor and Pfizer can help navigate these changes.
- Transition: Many patients have successfully transitioned between the two medications without significant issues, but it's important to monitor any changes in symptoms and report them to your healthcare provider.

It's always best to discuss any concerns with your healthcare provider to ensure a smooth transition and continued management of your condition.

 This AI-generated response comes from MyAmyloidosisTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Vyndaqel (Tafamidis meglumine) for Amyloidosis | MyAmyloidosisTeam

Wild-Type Amyloidosis — An Overview | MyAmyloidosisTeam